Skip to content
drillr.ai
Sign up

NTRA

Natera, Inc.

NASDAQ · Healthcare · Medical - Diagnostics & Research · US

$369.39
+0.84%
Ask drillr

  • Sep 18, 2026, 17:47 UTC

    Natera CEO and President Steven Leonard Chapman sold 1,698 shares of common stock on Sept. 1, 2026, under a Rule 10b5-1 plan amended in March 2026, per an SEC Form 4 filing.

    Source:

  • Sep 18, 2026, 10:00 UTC

    Natera presented new data on its Signatera molecular residual disease test, including the largest MRD dataset in lung cancer, at the IASLC 2026 World Conference on Lung Cancer in Seoul, South Korea.

    Source:

  • Aug 28, 2026, 15:03 UTC

    Natera announced a national partnership with Susan G. Komen to accelerate breast cancer awareness and education, including efforts to increase understanding of minimal residual disease (MRD).

    Source:

  • Aug 27, 2026, 10:00 UTC

    Natera announced a collaboration with Angiex to use its Signatera test to assess response to Angiex's investigational antibody-drug conjugate AGX101 in a Phase I clinical trial.

    Source:

  • Aug 25, 2026, 09:29 UTC

    Callan Family Office LLC acquired a new position in Natera, Inc. by purchasing 3,582 shares valued at approximately $972,000 during the second quarter, as disclosed in a recent SEC filing.

    Source:

  • Aug 25, 2026, 07:55 UTC

    Brandywine Managers LLC acquired a new stake of 14,588 shares in Natera, Inc., valued at approximately $3,960,000, as disclosed in a Form 13F filing with the SEC.

    Source:

  • Aug 12, 2026, 10:00 UTC

    Natera announced a collaboration to support Kupando Therapeutics' Phase 1 clinical trial of KUP-101, using its Latitude assay to assess ctDNA dynamics in advanced skin cancers.

    Source:

  • Aug 7, 2026, 21:10 UTC

    Natera shares soared over 20% to an all-time high on August 7, 2026, boosting the co-founder's billionaire status.

    Source:

  • Aug 6, 2026, 20:05 UTC

    Natera reported financial results for the second quarter ended June 30, 2026, with total revenues of $752.8 million, up 37.7% year over year, and a gross margin of 64.5%.

    Source:

  • Aug 5, 2026, 10:00 UTC

    Natera submitted an application to Japan's PMDA for approval of its Signatera test as a companion diagnostic in muscle-invasive bladder cancer.

    Source:

  • Jul 16, 2026, 22:35 UTC

    MolDx finalized a local coverage determination (LCD) that expands coverage for Natera's Prospera portfolio in the surveillance setting for solid organ allograft rejection.

    Source:

  • Jul 9, 2026, 10:00 UTC

    Natera announced that its Signatera test received IVDR certification as a Class C device under the European Union's In Vitro Diagnostic Regulation.

    Source:

  • Jul 1, 2026, 16:01 UTC

    Natera (NTRA) and Aveta Biomics have partnered to use Natera's Signatera test in a global Phase 3 trial for head and neck cancer to assess minimal residual disease and treatment response.

    Source:

  • Jun 29, 2026, 10:00 UTC

    Natera and Aveta Biomics announced a strategic partnership to support Aveta's global Phase 3 registrational trial of APG-157 in head and neck cancer.

    Source:

  • Jun 25, 2026, 11:00 UTC

    Natera and Eledon Pharmaceuticals announced a strategic partnership to incorporate Natera's Prospera test into Eledon's planned Phase 3 kidney transplant trial.

    Source:

  • Jun 5, 2026, 00:00 UTC

    Natera, Inc. appointed Thomas Lynch as a Class I Director and member of the Board, effective June 2, 2026.